In Silico Analysis and Immunohistochemical Characterization of NaPi2b Protein Expression in Ovarian Carcinoma With Monoclonal Antibody Mx35

In Silico Analysis and Immunohistochemical Characterization of NaPi2b Protein Expression in Ovarian Carcinoma With Monoclonal Antibody Mx35

Author Soares, Ibere Cauduro Google Scholar
Simoes, Kleber Google Scholar
Santana de Souza, Jorge Estefano Google Scholar
Okamoto, Oswaldo Keith Autor UNIFESP Google Scholar
Wakamatsu, Alda Google Scholar
Tuma, Maria Carolina Google Scholar
Ritter, Gerd Google Scholar
Ferreira Alves, Venancio Avancini Google Scholar
Institution Universidade de São Paulo (USP)
Ludwig Inst Canc Res
Recepta Biopharma SA
Universidade Federal de São Paulo (UNIFESP)
Mem Sloan Kettering Canc Ctr
Abstract Introduction: Ovarian adenocarcinoma is frequently detected at the late stage, when therapy efficacy is limited and death occurs in up to 50% of the cases. A potential novel treatment for this disease is a monoclonal antibody that recognizes phosphate transporter sodium-dependent phosphate transporter protein 2b (NaPi2b).Materials and Methods: To better understand the expression of this protein in different histologic types of ovarian carcinomas, we immunostained 50 tumor samples with anti-NaPi2b monoclonal antibody MX35 and, in parallel, we assessed the expression of the gene encoding NaPi2b (SCL34A2) by in silico analysis of microarray data.Results: Both approaches detected higher expression of NaPi2b (SCL34A2) in ovarian carcinoma than in normal tissue. Moreover, a comprehensive analysis indicates that SCL34A2 is the only gene of the several phosphate transporters genes whose expression differentiates normal from carcinoma samples, suggesting it might exert a major role in ovarian carcinomas. Immunohistochemical and mRNA expression data have also shown that 2 histologic subtypes of ovarian carcinoma express particularly high levels of NaPi2b: serous and clear cell adenocarcinomas. Serous adenocarcinomas are the most frequent, contrasting with clear cell carcinomas, rare, and with worse prognosis.Conclusion: This identification of subgroups of patients expressing NaPi2b may be important in selecting cohorts who most likely should be included in future clinical trials, as a recently generated humanized version of MX35 has been developed.
Keywords ovarian carcinoma
phosphate transporter
NaPi2b
MX35
monoclonal antibody
Language English
Sponsor FINEP
Recepta Biopharma, Brazil
Date 2012-03-01
Published in Applied Immunohistochemistry & Molecular Morphology. Philadelphia: Lippincott Williams & Wilkins, v. 20, n. 2, p. 165-172, 2012.
ISSN 1062-3345 (Sherpa/Romeo, impact factor)
Publisher Lippincott Williams & Wilkins
Extent 165-172
Origin http://dx.doi.org/10.1097/PAI.0b013e318228e232
Access rights Closed access
Type Article
Web of Science ID WOS:000300644600010
URI http://repositorio.unifesp.br/handle/11600/34693

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account